M
Moyang Bio
Synthetic biology for medical aesthetic products
About Moyang Bio
Shanghai Moyom Biotechnology Co., Ltd. is a Chinese research, development, and production enterprise focused on the medical aesthetics market. The company is dedicated to creating a material platform based on calcium microspheres and CMC (carboxymethyl cellulose) gels. Its product pipeline includes superficial anti-aging skin products, with its core product, Moyan Microcrystalline, undergoing registration and evaluation as a national Class III medical device in China. Moyom Biotechnology operates in the high-tech enterprise sector, specializing in R&D, production, sales, and consulting services within the medical aesthetics field.
The company aims to enhance its internal research capabilities to provide high-standard products and professional technical services, positioning medical aesthetics within the essence of medicine.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Synthetic Biology, biomanufacturing, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Aug 2025 | $28M | $110M | Huagai Capital · BlueRun Ventures | ↗ |
| SERIES BEquity / VC | Nov 2024 | $0 | — | Undisclosed | — |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Moyang Bio in the Minhang District ecosystem
The Moyang Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Huagai Capital
BlueRun Ventures
Other known investors3 additional known investors
BioTrack Capital
Jinding Capital
Lanchi Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Moyang Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Moyang Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







